缺血性脑血管疾病的二级预防(PPT-65).ppt

缺血性脑血管疾病的二级预防(PPT-65).ppt

  1. 1、本文档共65页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
缺血性脑血管疾病的二级预防(PPT-65)

衡量任何政府成功或失败的最终评估标准应是其国民的满意度. 对政府而言,没有什么事情会比大众的健康更为重要,政府最关心的应是它的人民的健康. Franklin Delanor Roosevelt (1932) 卒中的危害性巨大,卒中具有多种危险因素 卒中是可以预防的,预防必须是循证的 病因分层是重要的发展方向 卒中预防必须依靠系统来实现 总 结 问 题 ? * * The recommendations for secondary prevention included in these guidelines are listed on this slide. At the top are the recommended approaches to risk factor reduction and life-style modification, followed by specific interventions studied to reduce risk. Carotid artery interventions include carotid endarterectomy and stenting. Specific recommendations are provided for the use of antithrombotic medications (both antiplatelet and anticoagulant), statins and blood pressure lowering with diuretics and ACE inhibitors. The use of angiotensin receptor blockers (ARBs) are also included. * This slide summarizes the relative risk reduction with secondary prevention therapies for ischemic stroke based on meta-analysis of existing trials. There are a number of medical therapies as well as life-style modifications that have been proven to reduce the risk of recurrent stroke. Applying these risk-reducing therapies to appropriate patients, in the absence of contraindications, could result in major benefits to patients hospitalized with stroke. * The HOPE trial, a secondary prevention study of patients with vascular disease or diabetes, including some stroke patients, showed reduction of events using the ACEI ramipril as monotherapy1. A primary prevention study in patients with hypertension and left ventricular hypertrophy, the LIFE trial, found the ARB losartan perferable to the beta-blocker atenolol, even though both achieved the same blood pressure control2. More recently, the MOSES trial, a prospective, randomized trial of hypertensive patients with a history of a cerebrovascular event within 24 months prior to randomization, found the ARB eprosartan reduced recurrent stroke significantly better than the calcium channel blocker nitrendipine despite equal blood pressure control3. 1The

文档评论(0)

wuyoujun92 + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档